JP2001519770A5 - - Google Patents

Download PDF

Info

Publication number
JP2001519770A5
JP2001519770A5 JP1998529056A JP52905698A JP2001519770A5 JP 2001519770 A5 JP2001519770 A5 JP 2001519770A5 JP 1998529056 A JP1998529056 A JP 1998529056A JP 52905698 A JP52905698 A JP 52905698A JP 2001519770 A5 JP2001519770 A5 JP 2001519770A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998529056A
Other languages
English (en)
Japanese (ja)
Other versions
JP4878664B2 (ja
JP2001519770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/023817 external-priority patent/WO1998028007A1/en
Publication of JP2001519770A publication Critical patent/JP2001519770A/ja
Publication of JP2001519770A5 publication Critical patent/JP2001519770A5/ja
Application granted granted Critical
Publication of JP4878664B2 publication Critical patent/JP4878664B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52905698A 1996-12-24 1997-12-23 安定な液体インターフェロン処方物 Expired - Fee Related JP4878664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
US60/034,353 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007133540A Division JP2007204501A (ja) 1996-12-24 2007-05-18 安定な液体インターフェロン処方物
JP2011220534A Division JP2012006979A (ja) 1996-12-24 2011-10-04 安定な液体インターフェロン処方物

Publications (3)

Publication Number Publication Date
JP2001519770A JP2001519770A (ja) 2001-10-23
JP2001519770A5 true JP2001519770A5 (cg-RX-API-DMAC10.html) 2004-10-28
JP4878664B2 JP4878664B2 (ja) 2012-02-15

Family

ID=21875893

Family Applications (5)

Application Number Title Priority Date Filing Date
JP52905698A Expired - Fee Related JP4878664B2 (ja) 1996-12-24 1997-12-23 安定な液体インターフェロン処方物
JP2007133540A Withdrawn JP2007204501A (ja) 1996-12-24 2007-05-18 安定な液体インターフェロン処方物
JP2011002557A Expired - Lifetime JP5851695B2 (ja) 1996-12-24 2011-01-07 安定な液体インターフェロン処方物
JP2011220534A Withdrawn JP2012006979A (ja) 1996-12-24 2011-10-04 安定な液体インターフェロン処方物
JP2014033581A Withdrawn JP2014098029A (ja) 1996-12-24 2014-02-25 安定な液体インターフェロン処方物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2007133540A Withdrawn JP2007204501A (ja) 1996-12-24 2007-05-18 安定な液体インターフェロン処方物
JP2011002557A Expired - Lifetime JP5851695B2 (ja) 1996-12-24 2011-01-07 安定な液体インターフェロン処方物
JP2011220534A Withdrawn JP2012006979A (ja) 1996-12-24 2011-10-04 安定な液体インターフェロン処方物
JP2014033581A Withdrawn JP2014098029A (ja) 1996-12-24 2014-02-25 安定な液体インターフェロン処方物

Country Status (27)

Country Link
EP (1) EP0948358B2 (cg-RX-API-DMAC10.html)
JP (5) JP4878664B2 (cg-RX-API-DMAC10.html)
KR (2) KR101042660B1 (cg-RX-API-DMAC10.html)
CN (2) CN1733296B (cg-RX-API-DMAC10.html)
AT (1) ATE270899T1 (cg-RX-API-DMAC10.html)
AU (1) AU738362B2 (cg-RX-API-DMAC10.html)
BG (2) BG65171B1 (cg-RX-API-DMAC10.html)
BR (1) BR9714434A (cg-RX-API-DMAC10.html)
CA (1) CA2275890C (cg-RX-API-DMAC10.html)
CZ (1) CZ300636B6 (cg-RX-API-DMAC10.html)
DE (1) DE69729880T3 (cg-RX-API-DMAC10.html)
DK (1) DK0948358T4 (cg-RX-API-DMAC10.html)
EA (1) EA002754B1 (cg-RX-API-DMAC10.html)
EE (2) EE04223B1 (cg-RX-API-DMAC10.html)
ES (1) ES2224290T5 (cg-RX-API-DMAC10.html)
HU (1) HU224222B1 (cg-RX-API-DMAC10.html)
IL (1) IL130524A (cg-RX-API-DMAC10.html)
IS (1) IS2070B (cg-RX-API-DMAC10.html)
MX (1) MX337876B (cg-RX-API-DMAC10.html)
NO (1) NO327844B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ336548A (cg-RX-API-DMAC10.html)
PL (1) PL193447B1 (cg-RX-API-DMAC10.html)
PT (1) PT948358E (cg-RX-API-DMAC10.html)
SI (1) SI0948358T2 (cg-RX-API-DMAC10.html)
SK (1) SK284989B6 (cg-RX-API-DMAC10.html)
TR (1) TR199901968T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998028007A1 (cg-RX-API-DMAC10.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドの液体組成物
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CA2546280A1 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
BRPI0514408B8 (pt) * 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE602005011321D1 (de) * 2004-11-10 2009-01-08 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
EP1845925B1 (en) * 2005-01-12 2016-08-24 Biogen MA Inc. Method for delivering interferon-beta
AU2006206272A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP2264162A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
RS52417B (sr) 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2531657T3 (es) 2008-05-01 2015-03-18 Arecor Limited Formulación de una proteína
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2649993B1 (en) 2010-12-09 2017-04-05 Maruishi Pharmaceutical Co., Ltd. Stabilizer of acetaminophen
CA2846786C (en) 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
MX2014012461A (es) * 2012-04-19 2015-01-12 Bard Inc C R Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程(集团)股份有限公司 一种重组人干扰素α2b制剂
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
CN121371151A (zh) 2014-12-03 2026-01-23 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
US20230159605A1 (en) * 2020-04-29 2023-05-25 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
EP4313211A1 (en) * 2021-03-30 2024-02-07 SCHOTT Pharma Schweiz AG System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
JP2025501169A (ja) * 2021-12-27 2025-01-17 エナラーレ セラピューティクス インコーポレイテッド 呼吸刺激薬非経口製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon
TW249202B (cg-RX-API-DMAC10.html) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen

Similar Documents

Publication Publication Date Title
JP2000510408A5 (cg-RX-API-DMAC10.html)
JP2000511776A5 (cg-RX-API-DMAC10.html)
JP2000508911A5 (cg-RX-API-DMAC10.html)
JP2000508223A5 (cg-RX-API-DMAC10.html)
JP2001503577A5 (cg-RX-API-DMAC10.html)
JP2001507178A5 (cg-RX-API-DMAC10.html)
JP2001502318A5 (cg-RX-API-DMAC10.html)
JP2000512523A5 (cg-RX-API-DMAC10.html)
JP2001505897A5 (cg-RX-API-DMAC10.html)
JP2001517128A5 (cg-RX-API-DMAC10.html)
JP2001502303A5 (cg-RX-API-DMAC10.html)
JP2000503414A5 (cg-RX-API-DMAC10.html)
JP2001500643A5 (cg-RX-API-DMAC10.html)
JP2000508541A5 (cg-RX-API-DMAC10.html)
JP2001501223A5 (cg-RX-API-DMAC10.html)
JP2000507001A5 (cg-RX-API-DMAC10.html)
JP2000515866A5 (cg-RX-API-DMAC10.html)
JP2000515141A5 (cg-RX-API-DMAC10.html)
JP2000505485A5 (cg-RX-API-DMAC10.html)
JP2001510338A5 (cg-RX-API-DMAC10.html)
JP2000508682A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2001504877A5 (cg-RX-API-DMAC10.html)
JP2000512483A5 (cg-RX-API-DMAC10.html)
JP2000512676A5 (cg-RX-API-DMAC10.html)